NEW YORK (TheStreet) -- Shares of Abbott Laboratories (ABT) - Get Report are higher by 1.47% to $40.75 in mid-afternoon trading on Wednesday, ahead of the company's 2015 fourth quarter earnings results.
The Abbott Park, IL-based company reports its earnings results before the market open on Thursday.
Analysts surveyed by Thomson Reuters are expecting Abbott to report earnings of 61 cents per share on revenue of $5.22 billion.
The company reported earnings of 71 cents per diluted share, excluding items, on revenue of $5.36 billion during the same period the year prior.
Abbott is engaged in the discovery, development, manufacture and sale of a range of health care products.
Separately, TheStreet Ratings Team has a "buy" rating with a score of B- on the stock.
This is driven by a number of strengths, which should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks it covers.
The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins.
The team believes its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: ABT